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Volume 51, Number 5 Abstracts 1321of Diet and Renal Disease equation (Kidney Intern 1999;55:1878-84). The
medically treated patients’ risk with high-grade ICA stenosis (70%) for
ipsilateral stroke at 2 years was higher in patients with CKD then in those
with preserved renal function (31.6% vs 19.3%; P  .042). Carotid endar-
terectomy reduced this risk by 82% and 51%, respectively. Prevention of one
stroke in terms of numbers needed to treat was 10 for patients with preserved
renal function. However, the number needed to treat to prevent one stroke
was only four in patients with CKD. Patients with CKD had similar rates of
perioperative stroke and death but higher rates of perioperative cardiac
deaths than patients without CKD.
Comment: Twelve years after its initial publication, the NASCET trial
is still spinning off interesting—but very thinly sliced—additional pieces of
salami. Patients with CKD can be inappropriately denied interventions
because of perceived, but not proven, high risk. This phenomenon has been
termed “renalism” (J Am Soc Nephro 2004;15:246.2468). The article is
interesting because it not only reports patients with symptomatic high-grade
ICA stenosis and CKD appear to drive significant benefit from endarterec-
tomy but also raises the concept that patients with CKD, although at higher
risk with certain procedures, may actually, in the long-term, derive increased
benefit over those without CKD. Also, as the authors pointed out, large
randomized trials should consider enrolling, rather than somewhat arbi-
trarily excluding, patients with CKD. CKD patients may actually derive
unexpected and substantial benefit from selected procedures.
Collected World and Single Center Experience with Endovascular
Treatment of Ruptured Abdominal Aortic Aneurysms
Veith FJ, Lachat M, Mayer D, and the RAAA Investigators. Ann Surg
2009;250:818-24.
Conclusion: In some patients, endovascular repair of ruptured abdom-
inal aortic aneurysms (AAAs) has a lower procedural mortality at 30 days.
Summary: Endovascular aneurysm repair (EVAR) for ruptured AAA
was first reported in themid-1990s (Ann Surg 1995;222:449-65 and Lancet
1994;344:1645). Since then, EVAR for ruptured AAAs has been reported
with varying results. Some authors have concluded that EVAR results in
improved survival in patients with ruptured AAA, but others have reported
no better results with EVAR than traditional repair. Also, historic controls of
open repair results are often used to compare with modern results of EVAR.
All reports are case-series. There are no randomized trials comparing EVAR
and open repair in patients with similar anatomy and hemodynamic stability.
This article represents an attempt by the authors to summarize the
literature with respect to endovascular treatment of ruptured AAAs. The
authors examined a collective experience with use of EVAR to treat ruptured
AAAs from 49 centers. Each center provided data in the form of answers to a
questionnaire; in addition, a separate analysis was performed from 13 centers
committed to EVAR treatment for ruptured AAA whenever possible.
Information was obtained on 1037 patients treated by EVAR and 763
patients treated by open repair. In the 13 centers performing EVAR for
ruptured AAA whenever possible, EVAR was actually performed in a mean
of 49.1% of patients (range, 28%-79%). The 30-day mortality in 680 patients
treated with EVAR for ruptured AAA in these centers was 19.7% (range,
0%-32%). The 30-day mortality of the 763 patients treated with open repair
was 36.3% (range, 8%-53%; P 0.0001). Of the 1037 patients treated with
EVAR for ruptured AAA, 30-day mortality was 21.2%. In the 13 centers
using EVAR whenever possible, supraceliac aortic balloon control was
obtained in 19.1%  12%. An abdominal compartment syndrome was
treated by some form of decompression in 12.2%  8.3%.
Comment: One cannot argue with the conclusion EVAR has a lower
procedural mortality in “at least some patients” and may be preferable for
treating ruptured AAAs “provided that they (patients) have favorable anat-
omy; and adequate skills, facilities, and protocols are available, and optimal
strategies, techniques, and adjuncts are employed.” This is a classic “mom
and apple pie statement.” Whether or not it is correct or incorrect is actually
relatively unimportant. For the foreseeable future, individual surgeons will
need to make individual decisions for the treatment of ruptured AAA in
individual patients. I do not agree with Dr Veith that performing a random-
ized trial of open vs EVAR for treatment of matched patients with ruptured
AAA would be like performing a randomized trial on the use of parachutes.
I do agree with Dr Veith that such a trial would be difficult to perform and
that the performance of such a trial that provided results convincing to all
would be nearly impossible.
Efficacy of Aggressive Lipid Controlling Therapy for Preventing Sa-
phenous Vein Graft Disease
Hata M, Takayama T, Sezai A, et al. Ann Thorac Surg 2009;88:1440-4.
Conclusion: Aggressive lipid-controlling therapy may be effective in
preventing saphenous vein graft disease after coronary artery bypass grafting
(CABG).
Summary: About 25% of saphenous vein grafts occlude 1 year of
CABG, and 50% occlude  10 years (Am Heart J 1990;119:1164-84).
Despite their relative unfavorable natural history, saphenous vein grafts arestill used in70% of CABG procedures. It appears that plaque rupture with
thrombus formation are a major cause of long-term saphenous vein graft
disease after CABG (Circulation 2007;71:286-7). It also appears that low-
ering low-density lipoprotein cholesterol (LDL-C) 100 mg/dL may be
effective in reducing atherosclerosis in saphenous vein grafts. In this study,
the authors sought to investigate the efficacy of aggressive statin therapy on
angioscopic-determined progression of saphenous vein graft disease after
CABG.
There were 21 patients after CABG divided into two groups. Group I
comprised 10 patients whose serum LDL-C levels and LDL/high-density
lipoprotein (HDL) ratios could be controlled to 80 mg/dL and 1.5,
respectively. Group II consisted of 11 patients whose LDL-C levels and
LDL/HDL ratios were100mg/dL and2.5, respectively. Twenty-seven
saphenous vein grafts were assessed by intravascular ultrasound (IVUS) and
angioscopy at 12 to 16 months postoperatively.
Serum LDL-C levels in group I were 64.1 vs 130.2 mg/dL in group II.
LDL/HDL ratios in group I were 1.36 vs 2.64 in group II. High-sensitivity
C-reactive protein in group I was 0.045  0.1 vs 0.116  0.02 mg/dL in
group II. All values were significantly lower in group I. In group II, IVUS
detected eccentric plaques in 11 of 14 saphenous vein grafts (78.6%). Yellow
plaque was present in all 14 saphenous vein grafts by angioscopy, and 11 of
these grafts had thrombi. The 13 saphenous vein grafts in group I had no
eccentric or yellow plaques, and no thrombi were visible. The intima was
entirely clear white.
Comment: The mechanism of failure of saphenous vein grafts in the
coronary circulation may be different than that in the peripheral circulation.
However, the idea that driving down LDL-C and C-reactive protein levels
may improve vein graft patency is intriguing for the peripheral vascular
surgeon as well. Indeed, there is evidence suggesting higher primary assisted
and secondary patency in lower extremity vein grafts in patients treated with
statins (J Vasc Surg 2004;39:1178-85). Well-designed prospective data are
needed to assess the effects of statins on suppression of peripheral vein graft
lesions.
Randomized Comparison of Strategies for Type B Aortic Dissection:
The INvestigation of STEent Grafts in Aortic Dissection (INSTEAD)
Trial
Nienaber CA, Rousseau H, Eggebrecht H, et al. Circulation 2009;120;
2519-28.
Conclusion: In survivors of uncomplicated type B aortic dissection,
thoracic aortic stent grafts do not improve 2-year survival or adverse event
rates despite favorable aortic remodeling.
Summary: Thoracic endovascular aortic repair (TEVAR) was intro-
duced in 1999. The role of TEVAR in improving outcome in uncomplicated
type B aortic dissection is unknown. Stable patients undergoing medical
treatment with type B aortic dissection have an annual survival rate of80%;
however, aneurysm expansion and late complications do occur. Continued
perfusion of the false lumen is a risk factor for adverse outcomes, and
complete thrombosis of the false lumen has been associated with improved
outcome (Ann Thorac Surg 2007;83:1059-66 and Eur J Cardiothorac Surg
2004;26:359-66). The authors sought to determine whether placement of
thoracic aortic stent grafts might improve the prognosis in patients with
stable type B aortic dissection.
There were 140 patients who were clinically stable for at least 2 weeks
after an index type B aortic dissection. These patients were randomly
assigned to receive either elective stent graft placement in addition to
optimummedical therapy (n 72) or to optical medical therapy alone (n
68) with surveillance. Arterial pressure was treated according to World
Health Organization guidelines (attempting to achieve blood pressure of
120/80 mm Hg). All-cause death at 2 years was the primary end point.
Secondary end points were aortic-related deaths, progression (with need for
conversion or additional endovascular or open surgery), and aortic remod-
eling.
There was no difference in all-cause deaths between the two groups.
The 2-year cumulative survival was 95.6%  2.5% with optimum medical
therapy vs 88.9%  3.7% with TEVAR (P  .15). Aortic-related death rate
was not different (P  .44), and the risk for the combined end point of
aortic-related death (rupture) and progression (conversion or additional
endovascular or open surgery) was also similar (P  .65). There were three
adverse neurologic events in the TEVAR group and one patient with
transient paraparesis with medical treatment alone. Aortic remodeling (with
true lumen recovery and false-lumen thrombosis) occurred in 91.3% of
patients with TEVAR vs 19.4% of those who received medical treatment
alone (P  .004).
Comment: Uncomplicated type B aortic dissection managed with
tight blood pressure control and surveillance results in excellence survival
rates. At present, TEVAR can be considered an appropriate crossover
strategy if complications occur with a previously stable type B aortic dissec-
tion as, at least in this study, crossover patients uniformly survived deferred
TEVAR. The study supports, at least in the short-term, a complication-
specific approach to type B aortic dissection. Follow-up was relatively short
in this study, but even with short follow-up, favorable aortic remodeling
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Stent Graft versus Balloon Angioplasty for Failing Dialysis-Access
Grafts
Haskal ZJ, Trerotola S, Dolmatch B, et al. N Engl J Med 2010;362:494-
503.
Conclusion: Revision of a venous anastomotic stenosis of a prosthetic
dialysis access graft with a stent graft provides longer-term patency and
freedom from repeat intervention than revision with standard balloon an-
gioplasty.
Summary: Secondary patency of hemodialysis grafts is at best 50% at 3
years. Many interventions are typically required to maintain dialysis-access
graft patency. The authors sought to test the hypothesis that revision of
venous anastomotic stenosis with stent grafts constructed with the same
material as the dialysis-access graft itself would improve long-term patency
compared with that provided by revision with balloon angioplasty alone.
Theoretically, stent graft revision would prevent elastic recoil associated with
balloon angioplasty alone and prevent intimal hyperplasia in-growth at the
venous anastomosis, resulting in improved patency of the revised grafts.
This was a prospective multicenter trial. There were 190 patients
undergoing hemodialysis with dialysis-access grafts and a venous anastomo-
sis stenosis that were randomly assigned to receive balloon angioplasty alone
or balloon angioplasty plus placement of a stent graft at the site of the venous
anastomotic lesion. Patency of the treatment area and patency of the entire
vascular access graft were the primary end points.
At 6months, patency of the treatment area was greater in the stent graft
group than in the balloon angioplasty group (51% vs 23%, P  .001).
Six-month patency of the dialysis access circuit was improved in the stent
graft group vs the balloon angioplasty group (38% vs. 20%, P  .008).
Freedom from subsequent intervention at 6 months was also greater in the
stent graft group than in the balloon angioplasty group (32% vs 16%, P 
.03). Restenosis was greater in the balloon angioplasty group than in the
stent graft group (78% vs 28%, P .001). Other adverse events at 6 months
were equivalent in the two treatment groups.
Comment: There is still a need for dialysis-access grafts. Results of this
study suggest stent grafts provide better patency in treating venous anasto-
motic strictures of dialysis-access grafts than that provided by balloon
angioplasty alone. Although the results are statistically significant, there are
details to be considered before declaring the results clinically significant.
Grafts in this study were treated before actual thrombosis.Many access grafts
do not come to revision until they have thrombosed, and it is controversial
whether surveillance and treatment of patent, but not thrombosed dialysis
grafts, actually results in overall prolongation of usable access. In addition, 6
months after revision with a stent graft, there is primary patency in only half
the patients. Stent grafts are more expensive than balloon angioplasty alone.It is therefore unclear whether the increased patency at 6 months will
translate into longer-term cost-effectiveness and whether an approach of
graft surveillance with treatment with this technology of narrowed venous
anastomotic areas discovered with surveillance will result in meaningful
overall clinical benefit or cost savings.
White Blood Cell Count Predicts All-cause Mortality in Patients with
Suspected Peripheral Arterial Disease
Arain FA, Khaleghi M, Bailey KR, et al. Am J Med 2009;122:874.e1-
874.e7.
Conclusion: The white blood cell (WBC) count provides incremental
information about risk of death in patients with peripheral arterial disease
(PAD).
Summary: Inflammation is felt to play a central role in the develop-
ment and progression of atherosclerosis. Markers of inflammation associated
with higher rates of adverse cardiovascular outcome include C-reactive
protein (CRP) and WBC count as well as lipoprotein-associated phospho-
lipase A2. The authors postulated that increased plasma levels of CRP and
lipoprotein-associated phospholipase A2, as well as the WBC count, would
be associated with increased mortality in patients with suspected PAD
referred to a vascular laboratory.
The study population was derived from 242 patients (54% men; mean
age, 68 years) referred to a vascular laboratory. Ankle-brachial index (ABI)
and inflammatory markers were measured at the start of the study. Fifty-six
patients (25%) died in follow-up. Death was associated with increased age,
history of cerebrovascular or coronary artery disease, increased creatinine
level, lower ABI, increasedWBC count, and increased CRP level. Patients in
the top tertile of WBC count and CRP level had a relative risk of death of
3.37 (95% confidence interval, 1.56-7.27) and 2.12 (95% confidence inter-
val, 0.97-4.62), respectively. Lipoprotein-associated phospholipase A2 was
not associated with all-cause mortality. Only WBC count incrementally
contributed to prediction of mortality. Inferences were the same when
analysis was limited to patients with ABIs 0.9.
Comment: The data show indicators of systemic inflammation are
associated with higher mortality in patients referred to a vascular laboratory.
This study does not answer the question of whether WBC count is simply a
marker of inflammation or has an independent pathologic role. The top
tertile of WBC count in this study was defined 7.9  103/ml3; thus,
even patients with so-called normal WBC counts and PAD are at in-
creased risk of death. However, only about half of the patients were using
antiplatelet or statin medications, and it is unclear in the patients using
these medications over what proportion of the follow-up these medica-
tions were used. Before we start checking WBC counts in patients with
suspected PAD, this study will need to be repeated with patients who are
receiving aspirin and statin therapy.
